Literature DB >> 26962171

Complete Durable Response From Carboplatin and Olaparib in a Heavily Pretreated Triple-Negative Metastatic Breast Cancer With Germline BRCA2 and "BRCAness" Mutations.

Sanghee Hong1, Pauline Funchain2, Abdo Haddad2, Joseph Crowe2, Nancy Dalpiaz2, Jame Abraham2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26962171     DOI： 10.1200/JOP.2016.010710

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  4 in total

1.  Precision oncology in the age of integrative genomics.

Authors:  Chandan Kumar-Sinha; Arul M Chinnaiyan
Journal:  Nat Biotechnol       Date:  2018-01-10       Impact factor: 54.908

2.  H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer.

Authors:  S Mazzucchelli; M Truffi; F Baccarini; M Beretta; L Sorrentino; M Bellini; M A Rizzuto; R Ottria; A Ravelli; P Ciuffreda; D Prosperi; F Corsi
Journal:  Sci Rep       Date:  2017-08-08       Impact factor: 4.379

3.  Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells.

Authors:  Vojtech Novohradsky; Juraj Zajac; Oldrich Vrana; Jana Kasparkova; Viktor Brabec
Journal:  Oncotarget       Date:  2018-06-19

4.  Differential gene expression and AKT targeting in triple negative breast cancer.

Authors:  Feng-Mao Lin; Susan E Yost; Wei Wen; Paul H Frankel; Daniel Schmolze; Pei-Guo Chu; Yate-Ching Yuan; Zheng Liu; John Yim; Zhen Chen; Yuan Yuan
Journal:  Oncotarget       Date:  2019-07-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.